The psychopharmacology of violence: making sensible decisions

Leslie Citrome; Jan Volavka

Chapter 20 - The psychopharmacology of violence: making sensible decisions

from Section 5 - Psychopharmacology

Published online by Cambridge University Press: 19 October 2021

Leslie Citrome and

Jan Volavka

Edited by

Katherine D. Warburton and

Stephen M. Stahl

Show author details

Katherine D. Warburton: Affiliation:
University of California, Davis
Stephen M. Stahl: Affiliation:
University of California, San Diego

Book contents

Get access

Summary

A summary is not available for this content so a preview has been provided. Please use the Get access link above for information on how to access this content.

Image of the first page of this content. For PDF version, please use the ‘Save PDF’ preceeding this image.'

Type: Chapter
Information: Violence in Psychiatry , pp. 212 - 220

DOI: https://doi.org/10.1017/9781316135839 [Opens in a new window]

Publisher: Cambridge University Press

Print publication year: 2016

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Subscription

Individual access

Subscriptions are only available for individuals and not institutional access. Subscribe now

References

Swift, RH, Harrigan, EP, Cappelleri, JC, Kramer, D, Chandler, LP. Validation of the behavioural activity rating scale (BARS): a novel measure of activity in agitated patients. J. Psychiatr. Res. 2002; 36(2): 87–95.Google Scholar

Lindenmayer, JP, Brown, E, Baker, RW, et al. An excitement subscale of the Positive and Negative Syndrome Scale. Schizophr. Res. 2004; 68(2–3): 331–337.Google Scholar

Yudofsky, SC, Silver, JM, Jackson, W, Endicott, J, Williams, D. The Overt Aggression Scale for the objective rating of verbal and physical aggression. Am. J. Psychiatry. 1986; 143(1): 35–39.Google Scholar

Björkdahl, A, Olsson, D, Palmstierna, T. Nurses’ short-term prediction of violence in acute psychiatric intensive care. Acta Psychiatr. Scand. 2006; 113(3): 224–229.Google Scholar

Kay, SR, Opler, LA, Fiszbein, A. Positive and Negative Syndrome Scale Manual. North Tonawanda, NY: Multi-Health Systems; 2000.Google Scholar

Citrome, L, Green, L. The dangerous agitated patient: what to do right now. Postgrad. Med. 1990; 87(2): 231–236.Google Scholar

Citrome, L. Agitation III: pharmacologic treatment of agitation. In: Glick, RL, Berlin, JS, Fishkind, A, Zeller, S, eds. Emergency Psychiatry: Principles and Practice. Baltimore, MD: Lippincott Williams & Wilkins, Wolters Kluwer Health; 2008: 137–147.Google Scholar

Regier, DA, Farmer, ME, Rae, DS, et al. Comorbidity of mental disorders with alcohol and other drug abuse: results from the Epidemiologic Catchment Area (ECA) Study. JAMA. 1990; 264(19): 2511–2518.Google Scholar

Battaglia, J, Moss, S, Rush, J, et al. Haloperidol, lorazepam, or both for psychotic agitation? A multicenter, prospective, double-blind, emergency department study. Am. J. Emerg. Med. 1997; 15(4): 335–340.CrossRef Google Scholar PubMed

Brook, S, Lucey, JV, Gunn, KP. Intramuscular ziprasidone compared with intramuscular haloperidol in the treatment of acute psychosis: Ziprasidone I.M. Study Group. J. Clin. Psychiatry. 2000; 61(12): 933–941.Google Scholar

Daniel, DG, Zimbroff, DL, Swift, RH, Harrigan, EP. The tolerability of intramuscular ziprasidone and haloperidol treatment and the transition to oral therapy. Int. Clin. Psychopharmacol. 2004; 19(1): 9–15.Google Scholar

Brook, S, Walden, J, Benattia, I, Siu, CO, Romano, SJ. Ziprasidone and haloperidol in the treatment of acute exacerbation of schizophrenia and schizoaffective disorder: comparison of intramuscular and oral formulations in a 6-week, randomized, blinded-assessment study. Psychopharmacology (Berl.). 2005; 178(4): 514–523.Google Scholar

Wright, P, Meehan, K, Birkett, M, et al. A comparison of the efficacy and safety of olanzapine versus haloperidol during transition from intramuscular to oral therapy. Clin. Ther. 2003; 25(5): 1420–1428.Google Scholar

Andrezina, R, Marcus, RN, Oren, DA, et al. Intramuscular aripiprazole or haloperidol and transition to oral therapy in patients with agitation associated with schizophrenia: sub-analysis of a double-blind study. Curr. Med. Res. Opin. 2006; 22(11): 2209–2219.Google Scholar

Lesem, MD, Zajecka, JM, Swift, RH, Reeves, KR, Harrigan, EP. Intramuscular ziprasidone, 2 mg versus 10 mg, in the short-term management of agitated psychotic patients. J. Clin. Psychiatry. 2001; 62(1): 12–18.Google Scholar

Daniel, DG, Potkin, SG, Reeves, KR, Swift, RH, Harrigan, EP. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial. Psychopharmacology (Berl.). 2001; 155(2): 128–134.Google Scholar

Citrome, L. Comparison of intramuscular ziprasidone, olanzapine, or aripiprazole for agitation: a quantitative review of efficacy and safety. J. Clin. Psychiatry. 2007; 68(12): 1876–1885.CrossRef Google Scholar PubMed

Pfizer Inc. Geodon: US package insert for Geodon (ziprasidone HCl) capsules and Geodon (ziprasidone mesylate) injection for intramuscular use. September 2013. http://labeling.pfizer.com/ ShowLabeling.aspx?id=584. Accessed December 2, 2013.Google Scholar

Wright, P, Birkett, M, David, SR, et al. Double-blind, placebo-controlled comparison of intramuscular olanzapine and intramuscular haloperidol in the treatment of acute agitation in schizophrenia. Am. J. Psychiatry. 2001; 158(7): 1149–1151.Google Scholar

Breier, A, Meehan, K, Birkett, M, et al. A double-blind, placebo-controlled dose–response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch. Gen. Psychiatry. 2002; 59(5): 441–448.Google Scholar

Meehan, K, Zhang, F, David, S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J. Clin. Psychopharmacol. 2001; 21(4): 389–397.Google Scholar

Meehan, KM, Wang, H, David, SR, et al. Comparison of rapidly acting intramuscular olanzapine, lorazepam, and placebo: a double-blind, randomized study in acutely agitated patients with dementia. Neuropsychopharmacology. 2002; 26(4): 494–504.Google Scholar

Andrezina, R, Josiassen, RC, Marcus, RN, et al. Intramuscular aripiprazole for the treatment of acute agitation in patients with schizophrenia or schizoaffective disorder: a double-blind, placebo-controlled comparison with intramuscular haloperidol. Psychopharmacology (Berl.). 2006; 188(3): 281–292Google Scholar

Tran-Johnson, TK, Sack, DA, Marcus, RN, et al. Efficacy and safety of intramuscular aripiprazole in patients with acute agitation: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2007; 68(1): 111–119.CrossRef Google Scholar PubMed

Zimbroff, DL, Marcus, RN, Manos, G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J. Clin. Psychopharmacol. 2007; 27(2): 171–176.CrossRef Google Scholar PubMed

Rappaport, SA, Marcus, RN, Manos, G, McQuade, RD, Oren, DA. A randomized, double-blind, placebo-controlled tolerability study of intramuscular aripiprazole in acutely agitated patients with Alzheimer’s, vascular, or mixed dementia. J. Am. Med. Dir. Assoc. 2009; 10(1): 21–27.Google Scholar

Allen, MH, Feifel, D, Lesem, MD, et al. Efficacy and safety of loxapine for inhalation in the treatment of agitation in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. J. Clin. Psychiatry. 2011; 72(10): 1313–1321.Google Scholar

Lesem, MD, Tran-Johnson, TK, Riesenberg, RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br. J. Psychiatry. 2011; 198(1): 51–58.Google Scholar

Kwentus, J, Riesenberg, RA, Marandi, M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012; 14(1): 31–40.CrossRef Google Scholar PubMed

Citrome, L. Inhaled loxapine for agitation revisited: focus on effect sizes from 2 Phase III randomised controlled trials in persons with schizophrenia or bipolar disorder. Int. J. Clin. Pract. 2012; 66(3): 318–325.Google Scholar

Citrome, L. Addressing the need for rapid treatment of agitation in schizophrenia and bipolar disorder: focus on inhaled loxapine as an alternative to injectable agents. Ther. Clin. Risk Manag. 2013; 9: 235–245.Google Scholar

Merck & Co., Inc. Saphris: US package insert for Saphris (asenapine) sublingual tablets. March 2013. http://www.merck.com/product/usa/pi_circulars/s/saphris/saphris_pi.pdf. Accessed December 2, 2013.Google Scholar

Citrome, L. Asenapine for schizophrenia and bipolar disorder: a review of the efficacy and safety profile for this newly approved sublingually absorbed second-generation antipsychotic. Int. J. Clin. Pract. 2009; 63(12): 1762–1784.Google Scholar

Pratts, M, Citrome, L, Grant, W, Leso, L, Opler, LA. A single-dose, randomized, double-blind, placebo-controlled trial of sublingual asenapine for acute agitation. Acta Psychiatrica Scand. 2014 Jul; 130(1): 61–68.Google Scholar

Wilson, MP, Pepper, D, Currier, GW, Holloman, GH Jr, Feifel, D. The psychopharmacology of agitation: consensus statement of the American Association for Emergency Psychiatry Project Beta Psychopharmacology Workgroup. West. J. Emerg. Med. 2012; 13(1): 26–34.Google Scholar

Volavka, J, Citrome, L. Heterogeneity of violence in schizophrenia and implications for long-term treatment. Int. J. Clin. Pract. 2008; 62(8): 1237–1245.Google Scholar

Nolan, KA, Volavka, J, Czobor, P, et al. Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. J. Psychiatr. Res. 2005; 39(1): 109–115.Google Scholar

Nolan, KA, Volavka, J, Mohr, P, Czobor, P. Psychopathy and violent behavior among patients with schizophrenia or schizoaffective disorder. Psychiatr. Serv. 1999; 50(6): 787–792.CrossRef Google Scholar PubMed

Cooke, DJ, Michie, C. Refining the construct of psychopathy: towards a hierarchical model. Psychol. Assess. 2001; 13(2): 171–188.Google Scholar

Nolan, KA, Czobor, P, Roy, BB, et al. Characteristics of assaultive behavior among psychiatric inpatients. Psychiatr. Serv. 2003; 54(7): 1012–1016.Google Scholar

Citrome, L. New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia. Expert Rev. Neurother. 2013; 13(7): 767–783.Google Scholar

Volavka, J, Zito, JM, Vitrai, J, Czobor, P. Clozapine effects on hostility and aggression in schizophrenia. J. Clin. Psychopharmacol. 1993; 13(4): 287–289.Google Scholar

Citrome, L, Volavka, J, Czobor, P, et al. Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. Psychiatr. Serv. 2001; 52(11): 1510–1514.Google Scholar

Volavka, J, Czobor, P, Nolan, K, et al. Overt aggression and psychotic symptoms in patients with schizophrenia treated with clozapine, olanzapine, risperidone, or haloperidol. J. Clin. Psychopharmacol. 2004; 24(2): 225–228.Google Scholar

Krakowski, MI, Czobor, P, Citrome, L, Bark, N, Cooper, TB. Atypical antipsychotic agents in the treatment of violent patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry. 2006; 63(6): 622–629.Google Scholar

Citrome, L. Clozapine for schizophrenia: life-threatening or life-saving treatment? Current Psychiatry. 2009; 8(12): 56–63.Google Scholar

Volavka, J, Czobor, P, Derks, EM, et al. EUFEST Study Group. Efficacy of antipsychotic drugs against hostility in the European First-Episode Schizophrenia Trial (EUFEST). J. Clin. Psychiatry. 2011; 72(7): 955–961.Google Scholar

Volavka, J, Czobor, P, Citrome, L, Van Dorn, RA. Effectiveness of antipsychotic drugs against hostility in patients with schizophrenia in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) study. CNS Spectr. 2014; 0(5): 374–381. DOI: http://dx.doi.org/10.1017/S1092852913000849CrossRef Google Scholar

Kinon, BJ, Roychowdhury, SM, Milton, DR, Hill, AL. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia. J. Clin. Psychiatry. 2001; 62(Suppl 2): 17–21.Google Scholar

Citrome, L, Volavka, J. Pharmacological management of acute and persistent aggression in forensic psychiatry settings. CNS Drugs. 2011; 25(12): 1009–1021.Google Scholar

Citrome, L. Adjunctive lithium and anticonvulsants for the treatment of schizophrenia: what is the evidence? Expert Rev. Neurother. 2009; 9(1): 55–71.Google Scholar

Citrome, L, Levine, J, Allingham, B. Changes in use of valproate and other mood stabilizers for patients with schizophrenia from 1994 to 1998. Psychiatr. Serv. 2000; 51(5): 634–638.Google Scholar

Citrome, L, Shope, CB, Nolan, KA, Czobor, P, Volavka, J. Risperidone alone versus risperidone plus valproate in the treatment of patients with schizophrenia and hostility. Int. Clin. Psychopharmacol. 2007; 22(6): 356–362.Google Scholar

Huband, N, Ferriter, M, Nathan, R, Jones, H. Antiepileptics for aggression and associated impulsivity. Cochrane Database Syst. Rev. 2010;(2): CD003499.Google Scholar

Ratey, JJ, Sorgi, P, O'Driscoll, GA, et al. Nadolol to treat aggression and psychiatric symptomatology in chronic psychiatric inpatients: a double-blind, placebo-controlled study. J. Clin. Psychiatry. 1992; 53(2): 41–46.Google Scholar

Alpert, M, Allan, ER, Citrome, L, et al. A double-blind, placebo-controlled study of adjunctive nadolol in the management of violent psychiatric patients. Psychopharmacol. Bull. 1990; 26(3): 367–371.Google Scholar

Caspi, N, Modai, I, Barak, P, et al. Pindolol augmentation in aggressive schizophrenic patients: a double-blind crossover randomized study. Int. Clin. Psychopharmacol. 2001; 16 (2): 111–115.CrossRef Google Scholar PubMed